Recruiting

Early Phase 1

BotoxDuration of Botox Using OLD Versus COLD for Treatment of Glabellar Lines

Sponsor:

Clinical Testing of Beverly Hills

Code:

NCT05083286

Conditions

Glabellar Frown Lines

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Interventions

OnabotulinumtoxinA

Study Details

Brief summary:

This is a blinded, randomized study in the US to compare the duration response of two different concentrations of BOTOX in healthy female subjects with moderate to severe dynamic glabellar lines on maximum frown.

Conditions

Glabellar Frown Lines

Study ID

NCT05083286

Start date

Oct 20, 2021

Status verified date

Oct, 2021

Completion date

Aug 1, 2022

Anticipated

Primary completion date

Aug 1, 2022

Anticipated

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Accepted

Inclusion Criteria:

At least 18 years of age at the time of signing the informed consent.
Overtly healthy as determined by medical evaluation (includes: medical history, physical examination, and vital signs).
Subjects have moderate or severe dynamic glabellar lines on maximum frown as assessed with the Facial Wrinkle Scale.
Female sex.
Female subjects willing to minimize the risk of inducing pregnancy for the duration of the clinical study and follow-up period. A female subject is eligible to participate if she is not pregnant (has a negative urine pregnancy result at Day 1 prior to treatment), is not breastfeeding, and at least one of the following conditions applies: 1) not a female of childbearing potential or 2) a female of childbearing potential who agrees to follow the contraceptive guidance.
Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.
Written informed consent from the subject has been obtained prior to any study-related procedures.
Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable (eg, Written Authorization for Use and Release of Health and Research Study Information)
Able, as assessed by the blinded evaluating investigator, and willing to follow study instructions and likely to complete all required study visits

Exclusion Criteria:

Brow or eyelid ptosis, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin, or an inability to substantially lessen upper facial rhytids, even by physically spreading them apart.
Facial asymmetry including, in the opinion of the investigator, significant asymmetry with active contraction or at rest of the frontalis muscle.
Medical condition that may increase the subject's risk of exposure to botulinum toxin, including diagnosed myasthenia gravis, Lambert-Eaton Syndrome, amyotrophic lateral sclerosis, or any other disease that might interfere with neuromuscular function.
Profound atrophy/excessive weakness of muscles in target areas of injection.
History of facial nerve palsy.
Infection at the injection site or systemic infection.
Presence of inflammation at the proposed injection site.
Previous cosmetic surgery to the upper face (eg, periorbital surgery, brow lift, eyelid or eyebrow surgery), tissue grafting, or tissue augmentation with silicone or fat or other permanent fillers, or planning a facial cosmetic procedure during the study period.
Subjects have been treated in the upper face (forehead lines, glabellar lines, crow's feet lines) within 1 year prior to the Baseline/Day 1 Visit with botulinum toxin therapy of any serotype.
Noncompliance with the proper washout periods for prohibited medications/procedures.
Subjects on topical retinoid therapy and/or topical hormone cream applied to the face, who have not been on a consistent dose regimen for at least 6 months prior to enrollment and who are unable to maintain a consistent dose regimen during the study.
Oral retinoid therapy within 1 year prior to study enrollment.
Current enrollment in an investigational drug or device study or participation in such a study within 30 days of entry into this study.
Females who are pregnant, breastfeeding, or planning a pregnancy during the study.
Females of childbearing potential not using a reliable means of contraception.
Known allergy or sensitivity to the study treatment or its components.
Known immunization or hypersensitivity to any botulinum toxin serotype.
Prior exposure to or anticipated need for treatment with botulinum toxin of any serotype for any reason during the study (other than study treatment).
Evidence of recent alcohol or drug abuse.
The subject has a condition or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study.

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: OLD (4 U per 0.1 mL)

The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.5 mL.

active comparator: COLD (4 U per 0.02 mL group)

The total BOTOX dose will be 20U divided into 5 injections. Each injection will receive a total of 0.1 mL.

Interventions

OnabotulinumtoxinA

Injection of glabellar rhytids

Primary outcome measure

Response Duration [ Time Frame: 180 days ]

Central Contacts and Locations

Central contacts

Mary Hayes

747-998-5160 mary@clinicaltestingcenter.com

John Joseph, MD

8186163880 drjohnjoseph@sbcglobal.net

Locations

Clinical Testing of Beverly Hills

Recruiting

Encino, California, United States, 91436

Contacts

Mary Hayes

747-998-5160 mary@clinicaltestingcenter.com

Principal Investigator:

John Joseph, MD

Steve Yoelin MD

Recruiting

Newport Beach, California, United States, 92663

Contacts

Steve Yoelin, MD

747-998-5160

Principal Investigator:

Steve Yoelin, MD

More Information

Sponsor

Clinical Testing of Beverly Hills

Last update posted

Oct 27, 2021

Last verified

Oct, 2021

Keywords

wrinkles
onabotulinumtoxinA

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Clinical Testing of Beverly Hills on 2021-10-27.